News | Quality Assurance (QA) | February 06, 2018

Varian Acquires Mobius Medical Systems

The company’s acquisition expands its Quality Assurance tool portfolio

Varian Acquires Mobius Medical Systems

February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a radiation oncology Quality Assurance (QA) software company. This acquisition expands Varian's work in radiation medicine by increasing its portfolio of patient treatment plan QA and machine QA technologies and enables the company to potentially impact more patients around the globe with software solutions designed to assure the quality of treatments.

The acquisition of Mobius is consistent with Varian's long-term growth and value creation strategy and broadens its cancer care portfolio. The integration of additional QA tools into the Varian ecosystem will allow advanced QA processes to be more seamlessly combined into treatment workflows. Additionally, Varian also can ensure that QA methods advance at the same time as Varian introduces new treatment techniques.

“Varian places high value on the market-leading Mobius QA products, including Mobius3D and DoseLab, and is dedicated to expanding their global reach,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “The two companies have similar cultures with deep commitments to enabling quality cancer care for patients around the globe."

The Mobius QA software is in use at over 1000 sites worldwide to ensure patients receive high-quality care. Mobius3D is a 3-D dose verification and IMRT/VMAT treatment delivery QA system. Mobius3D performs 3-D dose verification for patient plans, supports verification checks throughout the entire clinical process for IMRT and VMAT, and includes modular staged testing to reinforce the confidence of the medical physicist in the patient plan and treatment delivery. DoseLab is fast, simple and powerful software for quality assurance of medical linear accelerators.

For more information: www.varian.com/mobius

Related Content

With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...
At the recent 2021 AAPM Meeting in July, Sun Nuclear Corporation featured its comprehensive portfolio of independent, integrated quality management solutions for radiation therapy and diagnostic imaging.
News | Quality Assurance (QA) | September 02, 2021
September 2, 2021 — At the recent 2021 AAPM Meeting
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.
RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ESTRO 2021, to be held in Madrid Aug. 27-30. Attendees will be able to book demonstrations of the RayStation treatment planning system, RayIntelligence the cloud-based oncology analytics system, and RayCare the oncology information system during the congress.
News | Radiation Oncology | August 30, 2021
August 30, 2021 — RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ...